4//SEC Filing
Haddadin Yezan Munther 4
Accession 0001209191-21-059950
CIK 0001649989other
Filed
Oct 6, 8:00 PM ET
Accepted
Oct 7, 5:06 PM ET
Size
5.8 KB
Accession
0001209191-21-059950
Insider Transaction Report
Form 4
Haddadin Yezan Munther
Director
Transactions
- Award
Stock Option (Right to Buy)
2021-10-05+47,335→ 47,335 totalExercise: $2.12Exp: 2031-10-05→ Common Stock (47,335 underlying)
Footnotes (1)
- [F1]The options were granted under the 2015 Plan in lieu of $82,500 cash fees payable under the Issuers's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.
Documents
Issuer
Outlook Therapeutics, Inc.
CIK 0001649989
Entity typeother
Related Parties
1- filerCIK 0001718004
Filing Metadata
- Form type
- 4
- Filed
- Oct 6, 8:00 PM ET
- Accepted
- Oct 7, 5:06 PM ET
- Size
- 5.8 KB